07:55 AM EST, 11/05/2025 (MT Newswires) -- Aurora Cannabis ( ACB ) , a Canada-based global medical cannabis company on Wednesday reported a loss in the second quarter of fiscal year 2026, despite its revenue beating analyst's expectations.

For the three-months ended Sept. 30, net loss from continuing operations was $53.2 million compared with a net income of $1.4 million, a year earlier. Adjusted net income was $7.1 million in Q2 compared with $3.0 million, a year-ago.

Total net revenue increased to $90.4 million, compared with $81.1 million in the prior year period, beating a consensus estimate compiled by FactSet of $86.4 million. The company said the increase was due to a 15% growth in its global medical cannabis business and a 34% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.

"These strong results affirm our strategic prioritization of medical cannabis as the industry's most compelling growth area," said Aurora Cannabis ( ACB ) chief executive Miguel Martin. "Looking ahead, we intend to deliver continued strong results for our shareholders supported by a sizable cash balance and debt-free cannabis business."

The company expects to see consolidated net revenue for Q3 2026, to increase year-over-year, driven primarily by 8% to 12% growth in its Global Medical Cannabis segment. Free cash flow is expected to be positive in Q3, due to "continued strong performance and improved operating cash use."

Shares of the company closed down 6.4% to $6.42 on Tuesday on the Toronto Stock Exchange.